

<b><u>Short Name</u></b>	<b><u>Comments</u></b>	<b><u>Type</u></b>	<b><u>Investigator</u></b>	<b><u>Contact</u></b>
CISTO	Comparison of Intravesical therapy and Surgery as Treatment Options for Bladder Cancer	Observational	SHORE Dr. Brian Lane	Zak Mulder zachary.mulder@spectrumhealth.org 616.391.2724
WF-1802	Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
NRG GU002	NRG GU002: Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA8153	Cabaz with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHARTED 2 Trial	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A031102	GERM CELL TUMORS/Relapsed or Refractory; Male Only; Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment. Phase III Trial	Treatment	CRCWM Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

A031501	<b>Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
AREN03B2	<b>COG-AREN03B2: Renal Tumors Classification, Biology, and Banking Study. Patients must be &lt;30 Years Old at the Time of Diagnosis</b>	Biobanking	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1802	<b>Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery Or Radiation) of The Primary Tumor in Metastatic Prostate Cancer</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
A031803	<b>Phase II Trial of Intravesical Gemcitabine and MK-3475 (pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
S1806	<b>Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

A031704	<b>PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE]</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA8171	<b>Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer</b>	Treatment	<b>CRCWM</b> Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
AREN1921	<b>Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
NRG CC007CD	<b>Increasing the Dose of Survivorship Care Planning In Prostate Cancer Survivors Who Receive Androgen Deprivation Therapy</b>	Cancer Care Delivery	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
NRG GU005	<b>A Phase III IGRT + SBRT vs IGRT + Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>
EA8143	<b>A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)</b>	Treatment	<b>CRCWM</b> Physician Investigators	CRCWM (616) 391-1230 <a href="http://www.crcwm.org">www.crcwm.org</a>

Merck 3475-641	A Phase III, Randomized, Double-blind, Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
Merck MK 3475-921	A Phase III, Randomized, Double-blind, Study of Pembrolizumab (MK-3475) Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)	Treatment	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
AstraZeneca (PREVAIL)	A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression Using the Ventana SP263 Assay in the First-line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma	Other	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>
AstraZeneca (NILE)	A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer	Biorepository	CHCWM Physician Investigators	CHCWM (616) 954-9800 <a href="http://www.chcwm.com">www.chcwm.com</a>